Beijing Baylx Biotech Co., Ltd is a national high-tech enterprise focused on stem cell and regenerative medicine research. For more than a decade, the company's core team has focused on stem cell basic research, new drug development, and clinical transformation.

It is China's first chair of the Committee for Standard of Quality Management for Stem Cell Manufacturing. charter trustee of the Biotechnology Association of China, provider of biological reference standard products and comparator products of HUCMSCs for NIFDC. It is a "Certificate of Confirming Manufacturing Quality Management for Stem Cell based Medical Products" holder. It is the only stem cell new drug developer invited to participate in the 2020 CIFTIS.

For more than a decade, the company's core team has focused on stem cell basic research, new drug development, and clinical transformation.

The core team members have presided over or participated in national 863, 973 projects and National Natural Science Foundation of China projects for many times, and published more than 50 papers. The company possesses cutting-edge stem cell preparation technology, a high technical level, and extensive quality control experience. It has developed a comprehensive and stable production process for stem cell preparations, as well as a strict and perfect quality control system, as well as a number of advanced stem cell preparation and quality detection technologies, and has declared and approved a number of invention patents.